AAM Hits Out At ‘Flawed’ Medicare Price Negotiation List

 
• By Dave Wallace
  
Price negotiation is creating barriers to competition and slowing down generic and biosimilar rivals (Shutterstock)

More from Drug Pricing

More from Generics Bulletin